Diorasis Therapeutics is a preclinical-stage company developing gene therapy for glaucoma.
Our disease-modifying gene agnostic single intracameral injection gene therapy produces tissue of modified plasminogen activator (tPA) that normalizes trabecular meshwork outflow and IOP.
Demonstrated significant efficacy :
Mice glaucoma model: outflow facility returned to normal, and IOP decreased to normal level after a single intracameral tPA GTx injection
Sheep glaucoma model: a single intracameral tPA-producing GTx injection dramatically decreased IOP to normal levels lasting until the end of 6 weeks experiment without any observed safety concerns
Normal mouse: no decrease in IOP (hypotony) after intracameral tPA GTx injection
Currently, we are conducting tox and IND-enabling studies to file IND
Company Details
- Employees
- 4
- Founded
- -
- Address
- 134 Coolidge Ave, Watertown,massachusetts 02472,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Northway Biotech.
- HQ
- Watertown, Massachusetts
Diorasis Therapeutics Questions
Diorasis Therapeutics's LinkedIn profile is https://www.linkedin.com/company/diorasis-therapeutics
Diorasis Therapeutics has
4 employees.
View email and phone details for 4
employees at Diorasis Therapeutics.
Diorasis Therapeutics's industry is
Biotechnology Research
Diorasis Therapeutics's top competitors are
Vq Biomedical,
Innoviama Llc,
Soteria Formulations,
Ligatrap™ Technologies, Llc,
Bioduro,
Allianthera Biopharma,
Dr. Falk Pharma,
Diorasis Group,
Virocell Biologics,
Northway Biotech.
Diorasis Therapeutics's categories are Biotechnology Research
Diorasis Therapeutics's founding year is 2022
